Petco Health and Wellness stock
WOOFNASDAQPetco Health and Wellness Company, Inc., Consumer CyclicalISIN US71601V1052
44Score 44 out of 100, Weak
Price and trend
69 / 100
Price history
−5.6% in one yearThe chart shows daily closes over 6 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 7.6% above it.
Since December 2025 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 65).
The price is 21% below its 52-week high. Largest decline in 6 years: 95% (January 2021 to April 2024).
Chart figures for advanced users
- SMA 50$2.48
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$2.67
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)65
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$2.18
- The lowest closing price of the last twelve months.
- Resistance$3.62
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Petco Health and Wellness Company, Inc. belongs to the Specialty Retail industry (United States) and, with a market value of $819.76M, is number 70 of 86 companies in its industry on MEQIRI.
- For fiscal 2026, analysts expect on average revenue of $5.99B (up 0.5%) and adjusted earnings per share of $0.26 (up 96.8%).
- MEQIRI Score 44 out of 100 (Weak): rank 518 of 596 in Consumer Cyclical, median 61.
Show more
- The P/E is 27.5 (Specialty Retail median 22.8, own median of recent years 34.5).
- Our model puts fair value at $2.60, with the price 10% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Earnings turn into cashFree cash flow above 500% of earnings over the last 12 months.
Weaknesses
- DilutionShare count up 37% since 2020.Capital allocation 25
- Interest barely coveredOperating profit covers interest only 1.1 times.Stability 28
- Volatile share priceVolatility 63% a year over the last 12 months.Stability 28
The score is held back by stability and capital allocation.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk medium
How well MEQIRI warnsIn the middle among smaller stocks.
From 2016 to 2025, 20 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- weak fundamentals
Valuation
Valuation signal
Fairly valuedIn our model the price counts as cheap below $1.74 and expensive above $5.21 (uncertainty very high, based on the price swings of the past year).
The two parts of the fair value come to $2.83 (cash-flow model) and $2.38 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is slightly above both parts; given how much the stock swings, that still counts as fair.
Calculated with a cost of equity of 12.8%. At 13.8% the fair value would be $2.47, at 11.8% it would be $2.77.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (22.8).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 1 Aug 2026, revenue fell 1.3% on the twelve months before. Revenue has grown solidly since 2018, at about 4% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 39%, operating 2%, net 0%.
Debt & balance sheet
latest quarterDebt is elevated. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 2 Dec 2026in 19 days
- Last reported
- 2 Sep 2026EPS reported $0.08 (expected $0.07)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $0.26+2.2%
- Revenue
- $5.99B0.0%
- Earnings per share
- $0.25+0.3%
- Revenue
- $6.05B−0.2%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: −2.3%Outlook reiterated, including full-year adjusted EBITDA, with net interest expense now about $122 million instead of $125 million.
“With regards to other line items, we now expect net interest expense to be about $122 million, down from $125 million, given we're now incorporating our $75 million debt repayment; depreciation and amortization, about $200 million; capital expenditures of about $140 million with an ongoing focus on ROIC; net store …”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 2 Sep 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. One insider sold, $1.15M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Petco Health and Wellness
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
596 rated companies in Consumer Cyclical
- This company
- 44
- Sector median
- 61
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Specialty Retail
The next larger and next smaller companies by market value
- D-Market Elektronik Hizmetler ve Ticaret A.S.HEPS $968.08M46
- WinmarkWINA $967.18M68
- DouglasDOU.DE $935.58M43
- SynsamSYNSAM.ST $882.67M65
- Cewe Stiftung & Co. KGaACWC.DE $811M71
- Fastned B.V.FAST.AS $758.78M41
- Betterware de Mexico, S.A.P.I. de C.V.BWMX $666.11M62
- Mobilezone Holding AgMOZN.SW $646.22M58
ETFs that hold Petco Health and Wellness
Held by 9 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| State Street SPDR MSCI USA Small Cap Value Weighted UCITS ETFZPRV | 0.02% | 0.30% | €964.08M |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.02% | 0.43% | €2.5B |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.02% | 0.10% | €395.74M |
Show 5 more
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.01% | 0.30% | €2.22B |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.01% | 0.30% | €4.28B |
| iShares MSCI World Small Cap UCITS ETFIUSN | 0.00% | 0.35% | €8.27B |
| UBS MSCI USA Select Factor Mix UCITS ETF USD accUSUE | 0.00% | 0.25% | €178.55M |
| State Street SPDR MSCI All Country World Investable Market UCITS ETF (Acc)SPYI | 0.00% | 0.17% | €8.84B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Jan 2026
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 Jan 2022)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.